#USA #Fremont #Alamar Biosciences #Alzheimer's Research #pTau217

Alamar Biosciences Breakthrough in Alzheimer’s Research

Alamar Biosciences has recently launched the NULISAqpcr™ BD-pTau217 test, marking a significant advancement in the non-invasive detection of brain-specific biomarkers pivotal for Alzheimer’s research. This test showcases a unique capability to quantify the phosphorylated tau 217 (pTau217) levels derived from the brain, a crucial biomarker for studying Alzheimer’s disease and other tauopathies.

This unique test offers unprecedented sensitivity and specificity using non-invasive samples like plasma, serum, and dried blood spots. Unlike traditional methods that require cerebrospinal fluid (CSF) or PET imaging, the NULISAqpcr BD-pTau217 enables researchers to bypass these challenges, facilitating comprehensive population studies and longitudinal clinical trials.

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, emphasized the groundbreaking nature of this test, stating, "The NULISAqpcr BD-pTau217 test redefines what’s possible in quantifying central nervous system biomarkers. By filtering out noise from peripheral tau sources, researchers can now detect significant cerebral changes earlier and with greater accuracy."

Leading neurologist Jonathan Schott, MD, PhD, from University College London further commended the performance of Alamar's pTau217 assays. He noted that preliminary results suggest the single-plex format is at least as effective as current pTau217 tests in plasma, but with a higher detection rate while minimizing the categorization of samples as indeterminate. This advancement is crucial for detecting asymptomatic individuals who may present high levels of Alzheimer's pathology, making them prime candidates for clinical trials involving disease-modifying therapies.

The NULISAqpcr BD-pTau217 is available for use as a standalone single-plex test or within the multiplex NULISAseq™ CNS Disease Panel 120. Its automated workflow can process over 220 samples per day using the ARGO™ HT system, making it ideal for high-throughput analysis in disease cohorts or population-based studies.

Alamar Biosciences is committed to collaborating with the neuroscience community to discover biomarkers that can accelerate advancements in Alzheimer’s disease research and beyond. More information can be found at alamarbio.com.

It is essential to note that the NULISA BD-pTau217 assays are strictly for research purposes and should not be employed in diagnostic procedures.

About Alamar Biosciences

Alamar Biosciences is a private company dedicated to life sciences, focused on developing precision proteomics to enable early disease detection. The company’s proprietary NULISA™ platform and the ARGO™ HT system work seamlessly with the latest genomic advancements, achieving detection sensitivity at attomolar levels, far surpassing any existing protein detection technologies on the market today. For further details, please visit alamarbio.com.